Compare Ganges Securitie with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.01%
- Poor long term growth as Net Sales has grown by an annual rate of -0.33% and Operating profit at -25.70%
Negative results in Dec 25
With ROE of 0.2, it has a Very Expensive valuation with a 0.2 Price to Book Value
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
Ganges Securitie for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Markets Rally, But Ganges Securities Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
While the broader market showed signs of recovery with the Sensex gaining over 2% today, Ganges Securities Ltd continued its downward trajectory, hitting a fresh 52-week low of Rs 105.5 on 24 Mar 2026. This decline extends a recent losing streak, underscoring persistent challenges for the micro-cap FMCG player despite a market environment that favours large caps.
Read full news article
Ganges Securities Ltd Stock Hits 52-Week Low at Rs.106 Amidst Weak Financials
Ganges Securities Ltd, a micro-cap player in the FMCG sector, touched a new 52-week low of Rs.106 today, marking a significant decline from its 52-week high of Rs.190. The stock’s performance reflects ongoing pressures from subdued financial results and valuation concerns, with the share price trading below all key moving averages.
Read full news article
Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 March 2026, providing investors with the latest insights into the stock’s performance and outlook.
Read full news article Announcements 
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)
20-Mar-2026 | Source : BSEDisclosure under Regulation 30
Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Feb-2026 | Source : BSENewspaper publication
Board Meeting Outcome for Outcome Of Board Meeting
11-Feb-2026 | Source : BSEPursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. February 11 2026 has inter-alia considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter year ended December 31 2025. A copy of Unaudited Financial Results along with Auditors Limited Report thereon is enclosed for your records; The meeting commenced at 3:45 p.m. and concluded at 4.30 p.m. The above is for your information and dissemination to all concerned.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 1 FIIs (0.03%)
Sil Investments Limited (13.38%)
Navjeewan Medical Institute (6.21%)
21.88%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -14.20% vs 1.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 82.50% vs -40.30% in Dec 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.41% vs 19.10% in Sep 2024
Growth in half year ended Sep 2025 is -52.87% vs 35.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -7.98% vs 11.81% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -41.05% vs 22.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 9.08% vs -15.57% in Mar 2024
YoY Growth in year ended Mar 2025 is 45.40% vs -64.31% in Mar 2024






